Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer

PURPOSE: Atypical, non-V600 BRAF (aBRAF) mutations represent a rare molecular subtype of metastatic colorectal cancer (mCRC). Preclinical data are used to categorize aBRAF mutations into class II (intermediate to high levels of kinase activity, RAS independent) and III (low kinase activity level, RA...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JCO Precis Oncol
Hlavní autoři: Johnson, Benny, Loree, Jonathan M., Jacome, Alexandre A., Mendis, Shehara, Syed, Muddassir, Morris II, Van K., Parseghian, Christine M., Dasari, Arvind, Pant, Shubham, Raymond, Victoria M., Vilar, Eduardo, Overman, Michael, Kee, Bryan, Eng, Cathy, Raghav, Kanwal, Kopetz, Scott
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2019
Témata:
Original Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446507/
https://ncbi.nlm.nih.gov/pubmed/32914034
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.19.00102
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky